title: Argatroban use during pediatric interventional cardiac catheterization.
abstract: Argatroban is a synthetic direct thrombin inhibitor that does not interact with or induce heparin-dependent antibodies. It is approved for use in adults for prevention and treatment of thrombosis associated with heparin-induced thrombocytopenia (HIT). It has been administered safely in adults with HIT during coronary interventions. There are no reports of argatroban use for anticoagulation in pediatric patients. The present case describes the use of argatroban during coil embolization of a Fontan fenestration in a child with a history of HIT. The patient received a single bolus dose of 150 microg/kg of argatroban at the onset of the intervention. The fenestration was successfully occluded with a detachable coil. The activated clotting time (ACT) was > 200 sec throughout the procedure. The ACT returned to baseline 72 min after the bolus. No complications occurred. This case demonstrates the safe and successful use of argatroban during a transcatheter intervention in a pediatric patient with a history of HIT. The use of argatroban is promising for anticoagulation in children who require an alternative to heparin.
authors.affiliation: Department of Pediatrics, Loyola University Medical Center, Maywood, Illinois, USA. cetta.frank@mayo.edu
authors.forename: Frank
authors.initials: F
authors.lastname: Cetta
authors.forename: Lynn C
authors.initials: LC
authors.lastname: Graham
authors.forename: Laura L
authors.initials: LL
authors.lastname: Wrona
authors.forename: M Janine
authors.initials: MJ
authors.lastname: Arruda
authors.forename: Jeanine M
authors.initials: JM
authors.lastname: Walenga
mesh_terms: D000991:Antithrombins / Q000008:administration & dosage*; D001120:Arginine / Q000031:analogs & derivatives; D006328:Cardiac Catheterization / Q000379:methods; D002648:Child; D004621:Embolization, Therapeutic / Q000379:methods*; D005343:Fibrinolytic Agents / Q000009:adverse effects; D006331:Heart Diseases / Q000150:complications / Q000628:therapy*; D006493:Heparin / Q000009:adverse effects; D006801:Humans; D008297:Male; D010875:Pipecolic Acids / Q000008:administration & dosage*; D013449:Sulfonamides; D013921:Thrombocytopenia / Q000139:chemically induced* / Q000150:complications; D013927:Thrombosis / Q000517:prevention & control
chemical_list: D000991:Antithrombins; D005343:Fibrinolytic Agents; D010875:Pipecolic Acids; D013449:Sulfonamides; D006493:Heparin; D001120:Arginine; C031942:argatroban